Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClearPoint NeuroCLPT +1.95%63 Beneish M-Score is 6.53 as of Aug. 12, 2026. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review. Among 766 Medical Devices & Instruments companies, ClearPoint Neuro ranks worse than 98.04% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score 6.53 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for ClearPoint Neuro's Beneish M-Score or its related term are showing as below:
CLPT'
s Beneish M-Score Range Over the Past 10 Years
Min: -4.3 Med: -2.92 Max: 6.53
Current: 6.53
During the past 13 years, the highest Beneish M-Score of ClearPoint Neuro was 6.53. The lowest was -4.30. And the median was -2.92.
The historical data trend for ClearPoint Neuro's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPT vs SI, PACB, DCTH: Beneish M-Score Comparison
For the Medical Devices subindustry, ClearPoint Neuro's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClearPoint Neuro Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of ClearPoint Neuro for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.5658
+
0.528 * 0.9651
+
0.404 * 22.3273
+
0.892 * 1.2586
+
0.115 * 0.9841
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1.1386
+
4.679 * -0.048916
-
0.327 * 1.2624
=
6.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(1.926 / (1.926 + 8.158))
/
(3.764 / (3.764 + 15.63))
=
0.190996
/
0.194081
=
0.9841
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-34.566 - -0.14
-
-30.183)
/
86.741
=
-0.048916
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
ClearPoint Neuro has a M-score of 6.53 signals that the company is likely to be a manipulator.
ClearPoint Neuro (CLPT) has a Beneish M-Score of 6.53 as of Aug. 12, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ClearPoint Neuro and its competitors. According to the industry distribution chart, ClearPoint Neuro ranks #751 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 98%.
Is ClearPoint Neuro's Beneish M-Score too high?
ClearPoint Neuro's current Beneish M-Score is 6.53. Based on the distribution chart, ClearPoint Neuro ranks #751 out of 766 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's Beneish M-Score compare to SI and PACB?
According to the Medical Devices & Instruments industry distribution chart, ClearPoint Neuro ranks #751 out of 766 companies for Beneish M-Score. This places ClearPoint Neuro in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ClearPoint Neuro and its competitors. ClearPoint Neuro's current Beneish M-Score is 6.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $15.16 — trading 7.2% above its estimated fair value. The current Beneish M-Score is 6.53. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current Beneish M-Score is 6.53 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClearPoint Neuro (CLPT) Overvalued in 2026?
Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued.
The current stock price of $15.16 is trading 7.2% above its estimated GF Value™ of $14.14.
GuruFocus considers ClearPoint Neuro to be Fairly Valued.
Key valuation signals for CLPT:
Beneish M-Score: 6.53
GF Value™: $14.14 vs. price of $15.16 (7.2% above fair value)
No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score
Get the complete analysis for CLPT
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPT has been successfully added to your 
